2023年 | 腫瘍病態学分野

中野麻恵、島田能史、吉原弘祐、棗田学、石崎文雄、齋木琢郎、土田純子、松本吉史、村田雅樹、栗山洋子、上杉雅子、佐野美華、入月浩美、西野幸治、関根正幸、利川千恵、梅津哉、池亀史嗣、大橋瑠子、味岡洋一、西條康夫、川島寛之、今井千速、木下義晶、中川悟、横山直行、谷達夫、奥田修二郎、池内健、冨田善彦．新潟大学医歯学綜合病院におけるがんゲノム医療の現状と課題（2019年〜2022年）新潟医学会誌、137(8): 249-262, 2023.
Natsumeda M. Immune checkpoint blockade in malignant gliomas. J Clin Exp Med, 287(3):219-220, 2023.（和）
Natsumeda M. Pediatric-type diffuse high-grade gliomas. No Shinkei Geka, 51(5):876-881, 2023.（和）
Tsukamoto Y, Natsumeda M, Takahashi H, Ueno A, Sakai K, Shida K, Seto H, Saito T, Shibuma S, Nakayama Y, Tanaka Y, Nakano T, Ohta A, Maruyama K, Okada M, Eda T, Seki Y, Yoneoka Y, Shimizu H, Okamoto K, Kakita A, Oishi M. Clinical, imaging, and molecular features of radiation-induced glioblastomas developed more than 20 years after radiation therapy for intracranial germinomatous germ cell tumor. JNS Case Lessons, 6(16):CASE23361, 2023.
Kitahara S, Kanazawa M, Natsumeda M, Sato A, Ishikawa M, Hara K, Tabe H, Makino K, Okamoto K, Fujita N, Kakita A, Fujii Y, Onodera O. Progressive conus medullaris lesions are suggestive of intravascular large B-cell lymphoma. Eur J Neurol, 30(10):3236-3243, 2023.
Yamasaki F, Fudaba H, Asano K, Sasayama T, Natsumeda M, Shimabukuro T, Taguchi K, Koizumi S, Nakayama N, Fujii K, Nishibuchi I, Sugiyama K, Yoshida S, Nakayama N, Momii Y, Kawasaki Y, Kakuta K, Katayama K, Tanaka K, Nagashima H, Tsukamoto Y, Ideguchi M, Nishizaki T, Kurozumi K, Hosoya T, Akita T, Kambe A. Study protocol for a phase II, multicentre, non-randomised study of multidrug chemotherapy, whole-brain radiation, and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment. BMJ Open, 13(4):e071350, 2023.
Takahashi H, Natsumeda M, On J, Watanabe J, Tada M, Shimizu H, Tsukamoto Y, Okada M, Oishi M, Takizawa J, Hayashi Y, Masaki Y, Kakita A, Fujii Y. Administration of glucocorticoids prior to liquid biopsy dramatically reduces the detection rate of MYD88 L265P mutation in cerebrospinal fluid of primary CNS lymphoma patients. Leuk Lymphoma, 64(6):1219-1222, 2023.
Tsukamoto Y, Natsumeda M, Takahashi H, On J, Seto H, Saito T, Shibuya K, Ogura R, Ito J, Okada M, Oishi M, Shimizu H, Okamoto K, Kakita A, Fujii Y. Diffusely infiltrating gliomas with poor prognosis, TERT promotor mutations and histological anaplastic pleomorphic xanthoastrocytoma-like appearance classify as mesenchymal type of glioblastoma, IDH-wildtype by methylation analysis. Neurosurg Practice, 4(2):1-11, 2023.
棗田学，温城太郎，渡邉潤，塚本佳広，岡田正康，小倉良介，平石哲也，大石誠，藤井幸彦．当科における光線力学療法の経験および次世代への挑戦．日本レーザー医学会誌，2023. (和)
Ando K, Natsumeda M, Kawamura M, Shirakawa K, Okada M, Tsukamoto Y, Eda T, Watanabe J, Saito S, Takahashi H, Kakita A, Oishi M, Fujii Y. Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas. Thromb Res, 223:36-43, 2023.
Mishima K, Nishikawa R, Narita Y, Mizusawa J, Sumi M, Koga T, Sasaki N, Kinoshita M, Nagane M, Arakawa Y, Yoshimoto K, Shibahara I, Shinojima N, Asano K, Tsurubuchi T, Sasaki H, Asai A, Sasayama T, Momii Y, Sasaki A, Nakamura S, Kojima M, Tamaru J, Tsuchiya K, Gomyo M, Abe K, Natsumeda M, Yamasaki F, Katayama H, Fukuda H. Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. Neuro-Oncol, 25(4):687-698, 2023.
Nakata S, Murai J, Okada M, Takahashi H, Findlay TH, Malebranche K, Parthasarathy A, Miyashita S, Gabdulkhaev R, Benkimoun I, Druillennec S, Chabi S, Hawkins E, Miyahara H, Tateishi K, Yamada S, Saito T, On J, Watanabe J, Tsukamoto Y, Yoshimura J, Oishi M, Nakano T, Imamura M, Imai C, Yamamoto T, Sasaki AT, Rodriguez FJ, Nobusawa S, Varlet P, Pouponnot C, Osuka S, Pommier Y, Kakita A, Fujii Y, Raabe EH, Eberhart CG, Natsumeda M. Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastoma sensitive to cisplatin. Neuro-Oncol, 25(5):899-912, 2023.